532 reports of this reaction
2.8% of all AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE reports
#2 most reported adverse reaction
FATIGUE is the #2 most commonly reported adverse reaction for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, manufactured by Novartis Pharmaceuticals Corporation. There are 532 FDA adverse event reports linking AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE to FATIGUE. This represents approximately 2.8% of all 18,930 adverse event reports for this drug.
Patients taking AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 532 FDA reports for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.8% of all adverse event reports for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience fatigue while taking AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.